Search Results - "Casadei, C."

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer by Cursano, M. C., Conteduca, V., Scarpi, E., Gurioli, G., Casadei, C., Gargiulo, S., Altavilla, A., Lolli, C., Vincenzi, B., Tonini, G., Santini, D., De Giorgi, U.

“…In localized prostate cancer (PCa), Grade Group (GG) and Gleason Score (GS) have a well-established prognostic role. In metastatic castration resistant…”
Get full text

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide by Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., De Giorgi, U.

“…Background Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients…”
Get full text

Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review by Cursano, M.C., Iuliani, M., Casadei, C., Stellato, M., Tonini, G., Paganelli, G., Santini, D., De Giorgi, U.

“…•In bone mCRPC, each treatment has an effect on PCa cells and bone microenvironment.•Clinical trials have been performed to evaluate radium 223-based…”
Get full text

A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management by C. Casadio, L. Galvani, A. De Giglio, C. Casadei, M.L. Tardio, B. Melotti, F. Sperandi, F. Gelsomino, F. Comito

“…Background: Immune checkpoint inhibitors (ICIs) have become the standard of care in several solid tumours. Thus the action of ICIs may lead to the development…”
Get full text

Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy by Casadei Gardini, A., Passardi, A., Fornaro, L., Rosetti, P., Valgiusti, M., Ruscelli, S., Monti, M., Casadei, C., Pagan, F., Frassineti, G.L.

“…The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However,…”
Get full text

Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial by Brighi, N., Conteduca, V., Gurioli, G., Scarpi, E., Cursano, M.C., Bleve, S., Lolli, C., Schepisi, G., Casadei, C., Gianni, C., Ulivi, P., De Giorgi, U.

“…Baseline plasma androgen-receptor copy number (AR-CN) is a promising biomarker for metastatic castration-resistant prostate cancer (mCRPC) outcome and…”
Get full text

Serial transverse enteroplasty (STEP) in case of short bowel syndrome: did we achieve our goal? A systematic review by Lauro, A., Santoro, A., Cirocchi, R., Michelini, M., Zorzetti, N., Cianci, M. C., Bellini, M. I., Casadei, C., Ripoli, M. C., Coletta, R., Khouzam, S., Marino, I. R., D’Andrea, V., Morabito, A.

“…Surveys on Serial Transverse Enteroplasty (STEP) published in international literature (1 January 2003– 31 May 2021) were searched. Articles were included from…”
Get full text

Local spin density in the Cr7Ni antiferromagnetic molecular ring and 53Cr-NMR by Casadei, C M, Bordonali, L, Furukawa, Y, Borsa, F, Garlatti, E, Lascialfari, A, Carretta, S, Sanna, S, Timco, G, Winpenny, R

“…We present (53)Cr-NMR spectra collected at low temperature in a single crystal of the heterometallic antiferromagnetic (AF) ring Cr(7)Ni in the S = 1/2 ground…”
Get more information

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum] by Casadei-Gardini, A, Montagnani, F, Casadei, C

“…Casadei-Gardini A, Montagnani F, Casadei C, et al. Cancer Manag Res. 2019;11:3631-3642. The authors have advised that the affiliations are not correct in the…”
Get full text

Randomness in time-resolved serial crystallography data: alternatives to the binning and averaging approach by Casadei, C., Hosseinizadeh, A., Schertler, G., Ourmazd, A., Santra, R.

“…Abstract only…”
Get full text

1809P Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial by Brighi, N., Wetterskog, D., Gurioli, G., Orlando, F., Conteduca, V., Casadei, C., Lolli, C., Giunta, E.F., Bleve, S., Vainauskas, O., Basso, U., Pierantoni, F., Fornarini, G., Mosca, A., Nicodemo, M., Banna, G.L., Ulivi, P., Demichelis, F., De Giorgi, U.F.F., Attard, G.

Get full text

601P The prognostic role of longitudinal assessment of plasma androgen receptor (AR) copy number (CN) in metastatic castration-resistant prostate cancer (mCRPC): Analysis from a prospective biomarkers trial by Brighi, N., Conteduca, V., Gurioli, G., Scarpi, E., Lolli, C., Schepisi, G., Casadei, C., Bleve, S., Ulivi, P., De Giorgi, U.

Get full text

OC.13.5 MOTORIZED SPIRAL ENTEROSCOPY: PRELIMINARY RESULTS OF A MULTICENTER, PROSPECTIVE, ITALIAN EXPERIENCE by Casadei, C., Fornaroli, F., Salvi, D., Michielan, A., Trebbi, M., Cavallaro, L., Olivari, N., Spada, C., De', Angelis G.L., De Pretis, G., Mussetto, A.

Get full text

583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide by Conteduca, V., Scarpi, E., Wetterskog, D., Brighi, N., Schepisi, G., Romanel, A., Casadei, C., Lolli, C., Gurioli, G., Toma, I., Poti, G., Farolfi, A., Demichelis, F., Attard, G., De Giorgi, U.

Get full text

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer by Conteduca, Vincenza, Wetterskog, Daniel, Scarpi, Emanuela, Romanel, Alessandro, Gurioli, Giorgia, Jayaram, Anuradha, Lolli, Cristian, Tandefelt, Delila Gasi, Schepisi, Giuseppe, Casadei, Chiara, Wingate, Anna, Matteucci, Federica, Paganelli, Giovanni, Gonzalez-Billalabeitia, Enrique, Demichelis, Francesca, De Giorgi, Ugo, Attard, Gerhardt

“…ABSTRACT Background Plasma tumour DNA (ptDNA) levels on treatment are associated with response in a variety of cancers. However, the role of ptDNA in prostate…”
Get full text

93PD - Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients by Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Morganti, R., Danesi, R., De Giorgi, U.F.F.

“…Abiraterone and enzalutamide represent the standard treatment in castration resistance prostate cancer (CRPC) patients, however, some patient displays primary…”
Get full text

Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients by Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Morganti, R., Danesi, R., De Giorgi, U.F.F.

Get full text

93PDAnalysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients by Del Re, M, Conteduca, V, Crucitta, S, Gurioli, G, Casadei, C, Restante, G, Schepisi, G, Lolli, C, Morganti, R, Danesi, R, De Giorgi, U F F

“…Abstract Background Abiraterone and enzalutamide represent the standard treatment in castration resistance prostate cancer (CRPC) patients, however, some…”
Get full text

Immune Inflammation Indicators Predict Outcome in Anal Cancer Patients Undergoing Concurrent Chemoradiation by Franco, P., Montagnani, F., Arcadipane, F., Casadei, C., Andrikou, K., Franco, G.C., Scartozzi, M., Mistrangelo, M., Fornaro, L., Cassoni, P., Cascinu, S., Ricardi, U., Casadei Gardini, A.

Get full text

800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy by Vignani, F., Hamzaj, A., De Giorgi, U., Tambaro, R., Basso, U., Gamba, T., Ermacora, P., Santini, D., Capacci, S., Casadei, C., Pignata, S., Bimbatti, D., Giannatempo, P., Atzori, F., Cavanna, L., Veccia, A., Scandurra, G., Doni, L., Aieta, M., Di Maio, M.

Get full text